FutureTechMedia

Immune Check Activators- Competitive Landscape, Technology and Pipeline Analysis, 2016

Press release   •   Jul 05, 2016 07:36 EDT

The Report deals with the TNFR/TNF superfamily members as agents of Cancer Immunotherapy that have brought a new dawn upon the existing therapies for cancer. Controlling diverse facets of immune function, it has brought into application a technology that rested in the pipeline for years. In the present scenario, members of the TNFR/TNF superfamily are being targeted to maintain, modulate and regulate body's own immune system to fight cancer. The rationale of this therapy is to mitigate/ avoid side effects, resistance, toxicity and pain brought by the combination therapy of surgery, radiation and chemotherapy. The future of this therapy lies strong as will be seen before 2020 as majority of its products will show results on safety, efficacy and dosing as they move to their Phase II trials in the provided timeline.

Complete Report Spread across 121 pages with 20 Figures Now Available, For Discount visit http://www.rnrmarketresearch.com/contacts/discount?rname=627363

Report Highlights

  • Immune Checkpoint Activators Therapy Pipeline scenario
  • Collaborations & partnering deals
  • Current Prominent Research Areas and Key Players
  • Pipeline product profiles Immune Checkpoint Activators Technologies and Targeted Antigens
  • Licensing opportunities
  • Market Drivers and Barriers

Order a Copy of This Report at http://www.rnrmarketresearch.com/contacts/purchase?rname=627363

List of Tables

Table 1: B7 & CD28 Family Members

Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2016

Table 3: Companies of Immune checkpoints Activators received grants, 2016

Table 4: Companies Investment Details for Immune checkpoints Activators, 2016

Table 5: Immune Check Targets-Number of Drugs (N) and Indications

Table 6: Immune Check Targets-Number of Drugs (N) and Indications

Table 7: Immune Check Activators Targets Antigens and Companies

Table 8: Immune Check Targets-Number of Trials (N) and Study Completion Year

Table 9: Number of Products Under Development for Immune checkpoints Activator, 2016

Table 10: Number of Products under Development by Companies, 2016

Table 11: Mid Stage Products (Phase II), 2016

Table 12: Early Stage Products (Phase I and IND), 2016

Table 13:Pre-Clinical and Discovery Products, 2016

Table 14: Assessment by Monotherapy Products, 2016

Table 15: Assessment by Combination Products, 2016

Table 16: Assessment by Route of Administration, 2016

Table 17: Assessment by Stage and Route of Administration, 2016

Table 18: Assessment by Molecule Type, 2016

Table 19: Assessment by Stage and Molecule Type, 2016

List of Figures

Figure 1: Immune Check Activators -Companies and Collaborations (N) and Investment (Million)

Figure 2: Immune Check Targets-Number of Products (N) and Total Share (%)

Figure 3: Immune Check Targets-Number of Drugs (N) and Indications

Figure 4: Immune Check Targets-Number of Products (N) and Stages of Development

Figure 5: Immune Check Targets-Number of Products (N) and Stages Of Development

Figure 6: Immune Check Targets-Number of Products (N) and Technology Used

Figure 7: Immune Check Targets-Number of Products (N) and Technology used

Figure 8: Immune Check Targets-Number of Trials (N) and Study Completion Year

Figure 9: Immune Check Targets-Study Completion Date, Indication and Recruitment status.

Figure 10: Immune Check Targets-Drugs and Study Completion Year

Figure 11: Number of Products under Development for Immune checkpoints Activator, 2016

Figure 12: Mid Stage Products (Phase II), 2016

Figure 13: Early Stage Products (Phase I and IND), 2016

Figure 14:Pre-Clinical and Discovery Products, 2016

Figure 15: Assessment by Monotherapy Products, 2016

Figure 16: Assessment by Combination Products, 2016

Figure 17: Assessment by Route of Administration, 2016

Figure 18: Assessment by Stage and Route of Administration, 2016

Figure 19: Assessment by Molecule Type, 2016

Figure 20: Assessment by Stage and Molecule Type, 2016

View More Details about This Report at http://www.rnrmarketresearch.com/immune-check-activators-competitive-landscape-technology-and-pipeline-analysis-2016-market-report.html

About Us:
RnRMarketResearch.com is your single source for all market research needs. Our database includes 100,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact Us:
We provide 24/7 online and offline support to our customers. Contact us for your special interest needs and we will get in touch within 24hrs to help you find the market research report you need.
sales@rnrmarketresearch.com
+ 1 888 391 5441